These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7826037)

  • 1. Human monoclonal antibodies for passive immunotherapy of HIV-1.
    Katinger H
    Antibiot Chemother (1971); 1994; 46():25-37. PubMed ID: 7826037
    [No Abstract]   [Full Text] [Related]  

  • 2. Neutralizing antibodies take a swipe at HIV in vivo.
    Montefiori DC
    Nat Med; 2005 Jun; 11(6):593-4. PubMed ID: 15937465
    [No Abstract]   [Full Text] [Related]  

  • 3. Passive immunization for the prevention and treatment of HIV infection.
    Zolla-Pazner S; Gorny MK
    AIDS; 1992 Nov; 6(11):1235-47. PubMed ID: 1472330
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunoprophylaxis against mother-to-child transmission of HIV-1.
    Gorny MK; Zolla-Pazner S
    PLoS Med; 2006 Jul; 3(7):e259. PubMed ID: 16842019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1.
    Jaworski JP; Cahn P
    Lancet HIV; 2018 Dec; 5(12):e723-e731. PubMed ID: 30245003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.
    Schoofs T; Klein F; Braunschweig M; Kreider EF; Feldmann A; Nogueira L; Oliveira T; Lorenzi JC; Parrish EH; Learn GH; West AP; Bjorkman PJ; Schlesinger SJ; Seaman MS; Czartoski J; McElrath MJ; Pfeifer N; Hahn BH; Caskey M; Nussenzweig MC
    Science; 2016 May; 352(6288):997-1001. PubMed ID: 27199429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Passive immunization for the treatment of HIV infection.
    Jacobson JM
    Mt Sinai J Med; 1998 Jan; 65(1):22-6. PubMed ID: 9458680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.
    Trkola A; Kuster H; Rusert P; Joos B; Fischer M; Leemann C; Manrique A; Huber M; Rehr M; Oxenius A; Weber R; Stiegler G; Vcelar B; Katinger H; Aceto L; Günthard HF
    Nat Med; 2005 Jun; 11(6):615-22. PubMed ID: 15880120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunology. Close to the edge: neutralizing the HIV-1 envelope.
    Nabel GJ
    Science; 2005 Jun; 308(5730):1878-9. PubMed ID: 15976295
    [No Abstract]   [Full Text] [Related]  

  • 10. Neutralizing antibodies against HIV -- back in the major leagues?
    Ferrantelli F; Ruprecht RM
    Curr Opin Immunol; 2002 Aug; 14(4):495-502. PubMed ID: 12088685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Trispecific broadly neutralizing antibodies for HIV immunoprophylaxis and immunotherapy?].
    Barin F; Stefic K
    Med Sci (Paris); 2018 Feb; 34(2):109-111. PubMed ID: 29451475
    [No Abstract]   [Full Text] [Related]  

  • 12. A summary of the workshop on passive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases, Bethesda, 10 March 2006.
    Bansal GP
    Biologicals; 2007 Oct; 35(4):367-71. PubMed ID: 17889555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal anti-CD4 as immunoprophylactic agents for human immunodeficiency virus infection.
    Attanasio R; Allan JS; Kennedy RC
    J Infect Dis; 1993 Aug; 168(2):515-6. PubMed ID: 8335999
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation.
    Stiegler G; Armbruster C; Vcelar B; Stoiber H; Kunert R; Michael NL; Jagodzinski LL; Ammann C; Jäger W; Jacobson J; Vetter N; Katinger H
    AIDS; 2002 Oct; 16(15):2019-25. PubMed ID: 12370500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant.
    Andrus L; Prince AM; Bernal I; McCormack P; Lee DH; Gorny MK; Zolla-Pazner S
    J Infect Dis; 1998 Apr; 177(4):889-97. PubMed ID: 9534960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection.
    Stiegler G; Katinger H
    J Antimicrob Chemother; 2003 Apr; 51(4):757-9. PubMed ID: 12654737
    [No Abstract]   [Full Text] [Related]  

  • 17. Passive immunization for the treatment and prevention of HIV infection.
    Karwowska S; Zolla-Pazner S
    Biotechnol Ther; 1991; 2(1-2):31-48. PubMed ID: 1845123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of anti-HIV-1 antibodies.
    Karpas A; Ash S; Bainbridge D
    Nat Med; 1997 Jun; 3(6):590-1. PubMed ID: 9176475
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunotherapy for HIV Infection.
    Weiss RA
    N Engl J Med; 2014 Jan; 370(4):379-80. PubMed ID: 24450898
    [No Abstract]   [Full Text] [Related]  

  • 20. HIV: Antibodies advance the search for a cure.
    Picker LJ; Deeks SG
    Nature; 2013 Nov; 503(7475):207-8. PubMed ID: 24172894
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.